Pipeline

Biomaker-based Drug
Development,MedPacto View more

Genome-based drug development
to overcome the limitations of existing anticancer drugs.

Through Biomarker-based Drug Development
We realize precision medicine.

Modulating Tumor Microenvironment
to improve the tumor-killing potency.

We are developing Innovative Treatment
for metabolic diseases and bone joint disease.

Vision & Mission

Biomaker-based Drug
Development,MedPacto

Vision

To contribute to humanity by developing innovative and
personalized therapies

Mission

To help all patients suffering from incurable diseases live
disease-free and healthy lives

  • Passion

    Transforming novel targets to innovative solutions for our patients

  • Scientific excellence

    Conducting ethically sound and transparent research & development Forming a strong team of industry experts

  • Mutual Collaboration

    Committed to improving the lives of patients Working together for shared benefits

R&D

Based on excellent technology, we discover and develop customized treatments for each patient.

Vactosertib

Vactosertib, a TGF-β signaling inhibitor
Vactosertib can be combined with
all existing cancer treatment

MA-B2/MO-B2

An antibody therapeutic targeting BAG2
Predicts metastasis and recurrence
of triple-negative breast cancer

MU-D201

Innovative agent inhibits TGF-β
signaling and epigenetic mechanisms
in cancer

Press Release

MedPacto's steps
forward for success continue. View more

MedPacto receives IND approval from the Ministry of Food and Drug Safety to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma

Feb 16, 2023

The efficacy of the combination treatment of Vactosertib with PRMT5 in pancreatic cancer was published in an international journal Cell Death and Disease (IF: 8.469)

Feb 15, 2023

MedPacto, identified the mechanism of action of the protein associated with the regulation of spermatogonial stem cell self-renewal

Feb 02, 2023

MedPacto hires global healthcare expert Namchol Park, as the Executive Vice President(EVP)

Jan 25, 2023

MedPacto receives U.S. FDA Fast Track designation for vactosertib for the treatment of metastatic osteosarcoma

Jan 17, 2023

Once at home on palliative care, a pediatric patient with osteosarcoma enjoys an active return to school and a prolonged progression-free period while on Vactosertib monotherapy.

Oct 10, 2022